Summary of Significant Accounting Policies (Details Narrative)		1 Months Ended		3 Months Ended
	Mar. 22, 2023 shares	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($) shares	May 11, 2023 USD ($)	Mar. 31, 2023 AUD ($)
Issuance of common stock | shares	5,000,000
FDIC insured amount				$ 250,000			$ 250,000
Uninsured amount				11,167,892			$ 0
Research and development expense				1,319,020	$ 629,531
Deferred offering costs				118,407
Foreign currency transaction gains and losses				$ (274)	$ 7,615
Stock Options and Warrants Exercisable [Member]
Antidilutive securities excluded from computation of earnings per share, amount | shares				2,168,742	1,729,734
Australian Tax Incentive [Member]
Research and development expense				$ 72,188	$ 35,960
Subsequent Event [Member] | ATM Facility [Member]
Long-Term Line of Credit						$ 2,611,843
Over-Allotment Option [Member]
Net proceeds		$ 2,913,750
IPO [Member]
Deferred offering costs				$ 56,724
Common Stock [Member]
Proceeds from Issuance Initial Public Offering			$ 18,648,934
Issuance of common stock | shares					630,000
Immix Biopharma Australia Pty Ltd. [Member]
Non-controlling interest rate				100.00%			100.00%